Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers

Clinical trial NCT06662825 · COMPLETED

Trial details

NCT number: NCT06662825
Sponsor: Novartis
Status: COMPLETED
Study type: OBSERVATIONAL

Sickle Cell Disease

Start date: 2022-12-13
Primary completion: 2023-11-01
Enrollment: 376

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.